Open Access
CC BY 4.0 · Brazilian Journal of Oncology 2025; 21
DOI: 10.1055/s-0045-1807928
PALLIATIVE CARE, SUPPORT AND END OF LIFE
1880
POSTER PRESENTATION

Awareness of chemotherapy-induced nausea and vomiting and adherence to guidelines in Brazil: results from thrive (training to help reduce CINV rates) program

Authors

  • Ridcardo Caponero

  • Nathalie Lapoint

  • Flávia Giudice

  • Diego Enrico

Further Information
 
  All articles of this category

    Keywords

    chemotherapy-induced-nausea-vomiting - CINV-rates - CINV-individual-RiskFactors - CINV-Guidelines-adherence

    Introduction: Chemotherapy-induced nausea and vomiting (CINV) is the most frequent and troubling adverse event during chemotherapy, significantly interfering with patient compliance and quality of life. Therefore, effective prophylactic measures are crucial for proper care. The THRIVE (Training to Help Reduce CINV ratEs) program, through a comprehensive multinational and multicenter personal practice assessment (PPA), evaluated the awareness and adherence of medical oncologists to established CINV management guidelines. Here, we report results from Brazilian practice.

    Objective: To evaluate medical oncologists' awareness of CINV and their adherence to CINV management guidelines.

    Methods: Twenty Brazilian clinical oncologists anonymously answered a survey about their own practice during a patient consultation. The PPA surveys were developed by four expert clinical oncologists from Argentina, Brazil and Canada.

    Results: Ninety percent (90%) of respondents declared adherence to international guidelines for determining CINV management protocols. However, 55% misclassified the emetogenic potential of highly emetogenic chemotherapy (HEC) and moderately emetogenic chemotherapy (MEC) regimens. Assessment of personal risk factors is essential to establish the best management of CINV; nevertheless, respondents did not discuss these factors with 56% of their patients. Additionally, there was a divergence between risk factors described in guidelines and those considered by respondents (i.e. only 25% of respondents consider gender as a risk factor). The assessment of these factors is particularly relevant for CINV prophylaxis in patients under treatment with MEC - although it is recommended to include a Neurokinin 1 receptor antagonist (NK-1 RA) in the regimen of patients with additional factors, only 60% of respondents actually use this strategy.

    Conclusion: There are significant disparities between clinical practices and guideline recommendations for CINV management in Brazil. Misclassification of emetogenic potential and inadequate assessment of personal risk factors highlight the need for continuous medical education to ensure optimal CINV management practices.

    Corresponding author: Flavia Giudice (e-mail: flavia.giudice@knighttx.com).


     

    No conflict of interest has been declared by the author(s).

    Publication History

    Article published online:
    06 May 2025

    © 2025. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution 4.0 International License, permitting copying and reproduction so long as the original work is given appropriate credit (https://creativecommons.org/licenses/by/4.0/)

    Thieme Revinter Publicações Ltda.
    Rua Rego Freitas, 175, loja 1, República, São Paulo, SP, CEP 01220-010, Brazil

    Bibliographical Record
    Ridcardo Caponero, Nathalie Lapoint, Flávia Giudice, Diego Enrico. Awareness of chemotherapy-induced nausea and vomiting and adherence to guidelines in Brazil: results from thrive (training to help reduce CINV rates) program. Brazilian Journal of Oncology 2025; 21.
    DOI: 10.1055/s-0045-1807928
      All articles of this category